Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Contact Us
HCPs
English
français
Canada
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts
History
Corporate Philosophy
About Takeda Canada
Message from the GM
Contact Us
Our Partnerships
Compliance
Takeda Worldwide
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Conditions We Treat
ADHD
Chronic Kidney Disease
Crohn's Disease
Gastro esophageal reflux disease (GERD, heartburn)
Gaucher Disease
Gout
Hereditary Angioedema
Hunter Syndrome
Lung Cancer
Multiple Myeloma
Short Bowel Syndrome
Type 2 Diabetes
Ulcerative Colitis
Our Medicines
Medications Return Program
Helping Canadian Patients
Our Pipeline of New Treatments
OnePath Patient Support Program
Vyvanse Assistance Program
How Takeda Canada does Business
Canadian R&D Initiatives
Our Stories
Our Stories
Find out Takeda's stories related on Innovation, Caring and Heritage
Learn more
Innovation
The Key Elements at the Heart of Our Innovation
Caring
Medicine for the World
IBD Patient Story
Multiple Myeloma Patient Story
#InTheirShoes
Rare Diseases Patient Story
Heritage
Takeda Canada's History
Keys to Aging Gracefully
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Our Commitment
Giving Back to the Community
Product Donations
Grants, Donations and Sponsorships
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
News Releases
News Releases
Enter
Year of release
2020
2019
2018
2017
2016
2015
2014
January, 2021
January 19, 2021
2021-01-19
Ready-to use self-injectable formulation of ENTYVIO® (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn’s disease and ulcerative colitis
November, 2020
November 5, 2020
2020-11-05
Eligible patients living with rare debilitating genetic disorder are one step closer to having access to first-of-its-kind treatment option
July, 2020
July 7, 2020
2020-07-07
Takeda Canada Announces New OnePath® Patient Support Program
July 2, 2020
2020-07-02
Amalgamation of Takeda Canada Inc. and Shire Pharma Canada ULC Solidifies Company’s Leadership Position in Canadian Biopharmaceutical Industry
May, 2020
May 11, 2020
2020-05-11
Updated COVID-19 Healthcare Professional Letter
April, 2020
April 9, 2020
2020-04-09
Self-injectable formulation of ENTYVIO® (vedolizumab) approved in Canada for the maintenance treatment of moderately to severely active ulcerative colitis
March, 2020
March 16, 2020
2020-03-16
COVID19 HCP Letter
February, 2020
February 4, 2020
2020-02-04
Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre
1
2
3
4
5
TOP